Clinical trials: Hypophosphatemia
Hypophosphatemia
Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia
The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.
- Trial name
- NCT06112236
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 250 people
- Sponsor
- University of Zurich
Anemia, Iron-deficiency
Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia
This is a confirmatory trial to establish superior serum phosphate stability associated with use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or iron deficiency anemia with Ferinject® before…
- Conditions
- Anemia, Iron-deficiency, Hypophosphatemia
- Trial name
- NCT05098249
- Testing
- Verum
- Where
- Switzerland
- Volunteers
- 92 people
- Sponsor
- Donat R. Spahn
Iron Induced Hypophosphatemia
Newborn Phosphocalcic Metabolism After Intravenous Iron Administration During Pregnancy
Iron deficiency anemia (IDA) is a very common health problem during pregnancy and intravenous (IV) iron substitution has become part of routine management.
- Trial name
- NCT06108258
- Testing
- IV iron administration
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
X-linked Hypophosphatemia
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab…
- Trial name
- NCT03920072
- Testing
- Burosumab
- Where
- 10 sites in France, Ireland and 2 more
- Volunteers
- 35 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
X-Linked Hypophosphatemia
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
The primary objectives of this study are to: Assess the long-term safety of KRN23 subcutaneous (SC) administration in adult subjects with XLH Assess the proportion of subjects achieving serum phosphorus levels in the normal range…
- Trial name
- NCT02312687
- Testing
- KRN23
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Kyowa Kirin, Inc.
Critically Ill
HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey
The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value < 0.8 mmol/l) in international critical care settings
- Trial name
- HYPO-P-ICU (NCT04201899)
- Testing
- No intervention - pure observation
- Where
- 4 sites in Estonia, France and 1 more
- Volunteers
- 890 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
X-linked Hypophosphatemic Rickets/Osteomalacia
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
- Trial name
- NCT02181764
- Testing
- KRN23
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 15 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Phosphate Deficiency, Phosphate Overload
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism
The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by diseases of phosphate metabolism, aimed at collecting and studying anamnestic, diagnostic, genetic…
- Trial name
- NCT06826664
- Where
- 28 sites in Italy
- Volunteers
- 100 people
- Sponsor
- F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
X-Linked Hypophosphatemia
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).
- Trial name
- NCT02915705
- Testing
- burosumab, Oral Phosphate Supplement, active vitamin D
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin, Inc.
Rendu Osler Disease
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case…
- Trial name
- OS-LERETRO (NCT05544669)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Strasbourg, France
Phosphate Diabetes, X-linked Hypophosphatemia
Phosphorus-31 Spectroscopy in Phosphate Diabetes
Phosphate diabetes is defined by urinary phosphate wasting due to impaired tubular reabsorption. It can be classified based on either a genetic or acquired origin.
- Trial name
- Phos-ATP (NCT06921720)
- Testing
- intra-muscular ATP values in phosphate diabetes, intra-muscular phosphate values in phosphate diabetes
- Where
- 2 sites in France
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Familial Hypophosphatemic Rickets
Calcimimetics in Hypophosphatemic Rickets
Currently, large oral doses of phosphate and 1,25(OH)2D (calcitriol) are the standard treatment of patients with familial hypophosphatemic rickets (XLH).
- Trial name
- CHR (NCT00844740)
- Testing
- Cinacalcet
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Hypophosphatemia, Familial, Rickets
Hypophosphatemic Rickets in Norway
The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence.
- Conditions
- Hypophosphatemia, Familial, Rickets, Hyperphosphatemia
- Trial name
- NCT01057186
- Testing
- Alfacalcidol; phosphate., Sevelamer
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
X-Linked Hypophosphatemia
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1.
- Trial name
- SUNFLOWER (NCT03745521)
- Testing
- no intervention
- Where
- Japan
- Volunteers
- 226 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypophosphatemia
FGF-23 Suppressibility by Calcitonin
Introduction: Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and…
- Trial name
- NCT00688077
- Testing
- Calcitonin
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Rijnstate Hospital
Refeeding Syndrome
Leptin, IGF1 and the Refeeding Index
Background and study hypothesis: Refeeding syndrome is a dangerous condition which could arise if patients who have had little or no food for many days, are started on any form of feeding.
- Trial name
- NCT01227850
- Volunteers
- 35 people
- Sponsor
- King's College Hospital NHS Trust
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Burosumab for CSHS
Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum…
- Trial name
- NCT03993821
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Laura Tosi
Hypophosphatemia, Infection
Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU
Retrospective study in the 3 intensive care units of the Brest Teaching Hospital (France) during a 18-months period (June 2014 -December 2015) to study the independent association between hypophosphatemia and 90-day mortality.
- Trial name
- PORPOISE-REA (NCT03529058)
- Where
- France
- Volunteers
- 193 people
- Sponsor
- University Hospital, Brest
Hypophosphatemia
Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.
The purpose of this clinical trial is to evaluate the efficacy and safety of Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the treatment of participants with mild, moderate, and severe hypophosphatemia.
- Trial name
- NCT07233889
- Testing
- Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Effect of Hypophosphatemia on Septic Patients
Hypophosphatemia Deleteriously Affects Outcome of Septic Shock Patients Admitted to ICU
Patients with severe sepsis/septic shock complicated by hypophosphatemia are at high risk of developing morbidities other than that underlying sepsis and more vulnerable to higher mortality rate.
- Trial name
- NCT04455113
- Testing
- Phosphorus level
- Where
- Egypt
- Volunteers
- 317 people
- Sponsor
- Ayman Anis Metry